TC-I 15
Cat. No.：YN300106
CAS No. ：916734-43-5
| 产品名称: | TC-I 15 |
| CAS No.: | 916734-43-5 |
| Chemical Name: | N-[[(4R)-5,5-Dimethyl-3-(phenylsulfonyl)-4-thiazolidinyl]carbonyl]-3-[[[(phenylmethyl)amino]carbonyl]amino]-L-alanine; (S)-3-(3-Benzylureido)-2-((R)-5,5-dimethyl-3-(phenylsulfonyl)thiazolidine-4-carboxamido)propanoic Acid; |
| Synonyms: | |
| 分子量: | 520.619 |
| 分子式: | C23H28N4O6S2 |
| SMILES: | 暂无 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | TC-I 15 (TC-I-15) 是一种变构型胶原结合整合素α2β1抑制剂，对与 GFOGER 和GLOGEN 结合的IC50分别为 26.8 μM 和 0.4 μM。TC-I 15 抑制血小板粘附胶原蛋白和血栓沉积。 |
| IC50和靶点: | [{name:"α2β1:0.4 (α2β1 μM (IC50)"},{name: "α2β1:26.8 (α2β1 μM (IC50)"},{name: "α1β1:23.6 (α1β1 μM (IC50)"},{name: "α1β1:24.4 (α1β1 μM (IC50)"},{name: "α11β1:177 (α11β1 μM (IC50)"},{name: "α11β1:3177 (α11β μM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Miller, M.W., et. al.: Proc. Natl. Acad. Sci. USA, 106, 719 (2009)
